OTCMKTS:BLUSF

BELLUS Health (BLUSF) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$6.46
$14.51
52-Week Range
N/A
Volume
3.45 million shs
Average Volume
39,610 shs
Market Capitalization
$2.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BLUSF stock logo

About BELLUS Health Stock (OTCMKTS:BLUSF)

BELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

BLUSF Stock News Headlines

Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Natura &Co Holding SA ADR NTCO
Raymond R. Blush
BELLUS Health: Q1 Earnings Insights
Where BELLUS Health Stands With Analysts
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
What's Going On With BELLUS Health's Stock Today?
See More Headlines
Receive BLUSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2019
Today
4/27/2024

Industry, Sector and Symbol

Sector
Medical
Industry
N/A
Sub-Industry
N/A
Current Symbol
OTCMKTS:BLUSF
CIK
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Net Income
$-7,010,000.00
Net Margins
-49,910.34%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$30,000.00
Book Value
$0.25 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.35 billion
Optionable
Not Optionable
Beta
1.55
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Roberto Bellini
    President, Chief Executive Officer & Director
  • François Desjardins
    Vice President-Finance
  • Denis Garceau
    Senior Vice President-Drug Development
  • Tony Matzouranis
    Vice President-Business Development
  • Sébastien Roy
    Secretary

BLUSF Stock Analysis - Frequently Asked Questions

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc (OTCMKTS:BLUSF) announced its earnings results on Wednesday, May, 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.01. The business had revenue of $0.01 million for the quarter. BELLUS Health had a negative net margin of 49,910.34% and a negative trailing twelve-month return on equity of 48.37%.

This page (OTCMKTS:BLUSF) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners